EpiBiologics, a San Mateo, CA-based biotechnology company building a next-generation antibody-based protein degradation platform, raised $50M in Series A funding.
The round was led by Mubadala Capital and Polaris Partners, with participation from Vivo Capital and GV.
Founded in 2022 and led by CEO Dr. Rami Hannoush, EpiBiologics is building a protein degradation platform that targets membrane and extracellular proteins. Its proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner.
The company intends to use the funds to expand and validate the platform, advance pipeline of drug candidates, and further build its team. To strengthen their leadership and support their expansion, EpiBiologics also announced the appointment of Shyra Gardai as its incoming Chief Scientific Officer. With over 20 years of scientific and pre-clinical drug development experience across multiple key therapeutic areas, Dr. Gardai has served in roles of increasing responsibilities in the biotechnology industry, including most recently as Vice President of Therapeutic Discovery Research at Seagen.
The company’s technology platform is based on the scientific work of EpiBiologics’ co-founder and renowned antibody engineer Dr. Jim Wells of the University of California, San Francisco (UCSF), and the platform intellectual property has been exclusively licensed from UCSF.
FinSMEs
22/03/2023